Alcon stock gains on Q2 2026 earnings beat and Berenberg Buy rating

Published on 09/13/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock is trading around USD 66 after Q2 2026 earnings showed EPS of USD 0.84 and a raised 2026 profit outlook. Analysts, including Berenberg Bank, see upside with targets near CHF 85.00 and around USD 85.85.

Photorealistic wide panoramic view of a modern ophthalmic surgery operating room. Surgical microscope centered, sterile metallic instruments arranged on blue drape, scrub-suited surgical team in background, cold overhead surgical lighting — Alcon CH0432492467: Augenchirurgie OP Saal mit Mikroskop, sterilen Werkzeugen und einem Operationsteam, Illustration mit AI erstellt.

Alcon Inc. (ISIN CH0432492467) stock recently traded around USD 66.03 on the New York Stock Exchange as of September 11, 2026, leaving the eye-care group valued at about USD 32.08 billion and positioned well below its analyst consensus price targets. According to an analyst overview on Pluang updated on September 12, 2026, Alcon reported Q2 2026 earnings per share of USD 0.84, beating estimates and prompting a raise to its 2026 profit outlook, which continues to underpin investor interest in the shares.Pluang

Q2 2026 earnings beat and outlook raise

According to Pluang, Alcon reported Q2 2026 EPS of USD 0.84, ahead of market expectations, and simultaneously raised its profit outlook for the 2026 financial year. The same source highlights that revenue for fiscal year 2025 reached USD 10.40 billion, while net income came in at USD 980 million, implying a net margin of about 9.42 percent for that year, although margin pressure has since eased as the company moved through 2026.Pluang

An earnings-call transcript for Q2 2026 indicates that Alcon achieved 7 percent sales growth in the quarter, supported by broad-based strength across its surgical and vision-care franchises.GuruFocus For investors, this combination of mid-single-digit revenue growth and an earnings beat suggests that the company is managing to push through higher volumes and improved mix while keeping costs under control. The raised 2026 profit guidance after the Q2 release reinforces the impression that management sees the positive trend continuing into the second half of the year.Pluang

Berenberg price target and analyst consensus

Alcon stock is currently supported by positive analyst commentary. In a report summarized by The Globe and Mail on September 12, 2026, Berenberg Bank analyst Sam England maintained a Buy rating on Alcon with a price target of CHF 85.00, while the company’s shares had closed at USD 66.72 in the prior session.The Globe and Mail Converted into dollar terms at prevailing mid-September 2026 exchange rates, that CHF 85.00 objective implies upside of more than 20 percent from the roughly USD 66 share price level, signaling that Berenberg still sees considerable appreciation potential based on the latest earnings trajectory.

The same Globe and Mail overview notes that the broader analyst community assigns Alcon a Moderate Buy consensus rating with an average price target around USD 87.74, well above the September 11, 2026 closing price of USD 66.03.The Globe and Mail A separate comparison piece on Pluang cites an analyst consensus Buy rating and an average target of about USD 85.85, compared with the same USD 66.03 share price, implying upside of roughly 30 percent if those forecasts are met.Pluang Together, these data points show that analysts reward Alcon’s Q2 2026 performance and raised outlook with price targets that sit substantially above the current market valuation.

Valuation, sector comparison and risks

Per Pluang’s cross-stock comparison updated in mid-September 2026, Alcon trades at USD 66.03 with a market capitalization of about USD 32.08 billion, while peers in other sectors such as SK Hynix or Nova Ltd carry different growth and risk profiles.Pluang With fiscal year 2025 revenue of USD 10.40 billion and net income of USD 980 million, Alcon’s implied price-to-sales and price-to-earnings multiples are supported by the expectation that Q2 2026’s 7 percent sales growth can be sustained or even modestly accelerated as new surgical platforms and contact-lens products roll out.Pluang

However, Pluang’s commentary also stresses that investors should monitor earnings consistency and macroeconomic headwinds, as a slowdown in global elective procedures or currency movements could affect the company’s 2026 profit trajectory.Pluang The raised profit outlook after Q2 2026 sets a higher bar for execution, so any deviation from the guided earnings path may prompt reassessment of those optimistic price targets. For now, though, the combination of Q2 2026 EPS of USD 0.84 above estimates, 7 percent quarterly sales growth and analyst targets clustered around CHF 85.00 and USD 85.85 keeps Alcon stock firmly in the Buy camp among many covering banks.

Stock level and next earnings date

On the primary listing at the New York Stock Exchange, Alcon stock closed at USD 66.03 on September 11, 2026, down 0.78% on the day, according to mid-September data used in several analyst and comparison overviews. With the shares trading noticeably below the USD 85-plus average analyst price targets yet supported by a Q2 2026 earnings beat and an improved 2026 profit outlook, the next major checkpoint for investors will be the upcoming quarterly report. An analyst overview cited by earlier market commentary lists November 10, 2026 as the next scheduled earnings date for Alcon, giving the market a clear calendar marker for reassessing the investment case in light of fresh numbers.